0001096906-19-000353.txt : 20191105 0001096906-19-000353.hdr.sgml : 20191105 20191105121513 ACCESSION NUMBER: 0001096906-19-000353 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191105 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 191192393 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 8-K 1 utah.htm 8K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):  November 5, 2019


UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
     
Utah
000-12575
87-0342734
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)

 


7043 South 300 West
  
Midvale, Utah
84047
(Address of principal executive offices)
(Zip code)
   
Registrant’s telephone number, including area code:
Phone: (801) 566-1200
   
n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
 
Emerging growth company [  ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]


ITEM 8.01—OTHER EVENTS

On November 5, 2019, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend.  A dividend of $.28 per share is payable on January 3, 2020 to shareholders of record at the close of business on December 13, 2019.  A copy of the press release is attached hereto as Exhibit 99.1


ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

The following is filed as an exhibit to this report:

Exhibit
Number*
  
 
Title of Document
  
 
Location
Item 99.1
  
Press release issued November 5, 2019: Utah Medical Products Inc. Increases Quarterly Dividend
  
This filing
_______________________________________
 
*
All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
UTAH MEDICAL PRODUCTS, INC.
   
Dated: November 5, 2019
By:
  /s/ Kevin L. Cornwell
   
Kevin L. Cornwell, Chief Executive Officer








EX-99 2 exh99_1.htm PRESS RELEASE ISSUED NOVEMBER 5, 2019: UTAH MEDICAL PRODUCTS INC. INCREASES QUARTERLY DIVIDEND
EXHIBIT 99.1

Salt Lake City, Utah ‑Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-eight cents ($.28) per share of common stock payable on January 3, 2020 to shareholders of record at the close of business on December 13, 2019. This is a 2% increase over the prior quarterly cash dividend.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients.  For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.